Key facts
- This page summarizes Chad J. Kolean's Form 4 filing for Cellectar Biosciences, Inc. (CLRB).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 24 Feb 2022, 16:00.
Chad J. Kolean - 22 Feb 2022 Form 4 Insider Report for Cellectar Biosciences, Inc. (CLRB)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- CLRB
- Reported as of
- 22 Feb 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 24 Feb 2022, 16:00:59 UTC
- Next SEC filing
- 15 Apr 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Asher M. Rubin, Attorneyin-fact for Chad Kolean
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Chad J. Kolean filed Form 4 for Cellectar Biosciences, Inc. (CLRB) on 24 Feb 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CLRB
transaction
Derivative
Stock option (right to buy)
Award
- Transaction value
- $0
- Shares
- +150,000
- Change %
- Price
- $0.000000
- Shares after
- 150,000
- Date
- 22 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 150,000
- Exercise price
- $0.4900
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
This option shall vest in three equal annual installments beginning on the first anniversary of the date of grant.